Bemarituzumab Elicits Positive Overall Survival in FGFR2b-Positive First-Line Gastric Cancer
Summary by Pharmacy Times
4 Articles
4 Articles
Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint
Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved its primary goal.The post Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium